Earnings Call · Q4 FY2023·2024-02-26

Q4 23EPS -29.55%·Rev n/aQ3 23EPS +1.00%·Rev n/aQ2 23EPS -12.20%·Rev n/aQ1 23EPS +10.00%·Rev n/a⚠ consensus missing

Revolution Medicines, Inc. RVMD

Erin Graves — Investor Relations

Mark Goldsmith — Chairman and Chief Executive Officer

Jack Anders — Chief Financial Officer

−2.8%1d on move date−2.6% vs SPY3d−3.5%5d−6.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RVMD calls or request research access.

More RVMD calls Browse calls Request research access